Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT04883996

A Phase 1/2 Crossover Study to Assess EXP039 for Myopia or Hyperopia

A Phase 1/2, Randomized, Placebo Controlled Crossover Study to Assess the Safety, Pharmacodynamics, and Efficacy of EXP039 Ophthalmic Solution in Participants With Myopia or Hyperopia

Sponsor: Canyon City Eyecare

Conditions Hyperopia Myopia

Interventions 1% EXP039 Saline control

Updated 4 times since 2021 Last updated: May 11, 2021 Started: Dec 1, 2020 Primary completion: Jul 31, 2021 Completion: Aug 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04883996, this PHASE1/PHASE2 trial focuses on Hyperopia and Myopia and remains ongoing. Sponsored by Canyon City Eyecare, it has been updated 4 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2023 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Enrolling By Invitation → Unknown Status
Jun 2021 — Jun 2023 [monthly]

Enrolling By Invitation PHASE1_PHASE2

First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Canyon City Eyecare
Nevakar, Inc.

Data source: Canyon City Eyecare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Azusa, United States